Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01609790
First received: May 30, 2012
Last updated: July 15, 2014
Last verified: May 2014
  Purpose

This partially randomized phase II trial studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab together with trebananib is more effective than bevacizumab alone in treating brain tumors.


Condition Intervention Phase
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Oligodendroglioma
Recurrent Adult Brain Tumor
Biological: bevacizumab
Biological: trebananib
Other: placebo
Other: pharmacological study
Other: laboratory biomarker analysis
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Incidence of dose-limiting toxicity (Cohort 1) [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
    Defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications.

  • PFS (Cohort 2) [ Time Frame: At 6 months ] [ Designated as safety issue: No ]
    The difference in PFS6 rates between the 2 treatments will be tested using a Z test for 2 proportions.


Secondary Outcome Measures:
  • Incidence of treatment-related toxicity, measured by CTCAE v. 4 [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
  • Feasibility of trebananib weekly in combination with bevacizumab every 2 weeks, measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent courses (Cohort 1) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Radiographic RR as measured by Revised Assessment in Neuro-Oncology response criteria (Cohort 2) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • PFS [ Time Frame: From the date of randomization to the date of first progression or death or, otherwise, the last follow-up date on which the patient is reported alive, assessed up to 2 years ] [ Designated as safety issue: No ]
    Will be estimated using the Kaplan-Meier method and differences between treatment arms will be tested in the log rank test.

  • OS (Cohort 2) [ Time Frame: From the date of randomization to the date of death or, otherwise, the last follow-up date on which the patient is reported alive, assessed up to 2 years ] [ Designated as safety issue: No ]
    Estimated using the Kaplan-Meier method and differences between treatment arms will be tested in the log rank test.

  • Tumor genotype, expression profile, and circulating angiogenesis biomarkers (Cohort 2) [ Time Frame: Up to 30 days post-treatment ] [ Designated as safety issue: No ]
    The association of tumor genotype, expression profile and circulating angiogenesis biomarkers with OS and PFS will be explored through log rank tests.


Estimated Enrollment: 141
Study Start Date: June 2012
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (bevacizumab and trebananib)
Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: bevacizumab
Given IV
Other Names:
  • anti-VEGF humanized monoclonal antibody
  • anti-VEGF monoclonal antibody
  • Avastin
  • rhuMAb VEGF
Biological: trebananib
Given IV
Other Names:
  • AMG 386
  • AMG386
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: laboratory biomarker analysis
Correlative studies
Active Comparator: Arm II (bevacizumab and placebo)
Patients receive bevacizumab as in arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.
Biological: bevacizumab
Given IV
Other Names:
  • anti-VEGF humanized monoclonal antibody
  • anti-VEGF monoclonal antibody
  • Avastin
  • rhuMAb VEGF
Other: placebo
Given IV
Other Name: PLCB
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess the safety and tolerability of AMG 386 (trebananib) 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1). (closed to accrual 10/2/12) II. To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naïve patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2).

SECONDARY OBJECTIVES:

I. To further assess the toxicity profile (Cohorts 1 and 2). II. To assess feasibility of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1 [closed to accrual 10/2/12]), as measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent cycles.

III. To determine the radiographic response rate (RR), median progression-free survival (PFS), and overall survival (OS) in bevacizumab-naïve patients (Cohort 2).

IV. To assess the efficacy of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks in patients who have progressed while on bevacizumab, as measured by overall survival (OS) (cross-over from placebo arm of Cohort 2).

V. To correlate outcome to treatment with tumor genotype, expression profile, and circulating angiogenesis biomarkers in tumor specimens (Cohort 2).

VI. To determine the RR, PFS6, and PFS in patients who have progressed while on bevacizumab therapy and receive AMG 386 in combination with bevacizumab (cross-over from placebo arm of Cohort 2).

VII. To determine the serum pharmacokinetics of AMG 386 in patients receiving bevacizumab (Cohort 1 and cross-over from placebo arm of Cohort 2).

OUTLINE: This is a safety study (cohort 1 [closed to accrual 10/2/12]) followed by a randomized study (cohort 2).

Cohort 1: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/2/12)

Cohort 2: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab and trebananib as in Cohort 1.

ARM II: Patients receive bevacizumab as in arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.

After completion of study treatment, patients are followed up at 30 days, every 2 months for 1 year, every 6 months for 1 year, and then annually thereafter.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven diagnosis of glioblastoma or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma); patients will be eligible if the original histology was a lower grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
  • The tumor must be supratentorial; patients with infratentorial disease, spinal cord disease, and/or leptomeningeal disease are excluded
  • Patients must have shown unequivocal evidence for tumor progression on the previous treatment regimen (prior to enrollment on this study) by magnetic resonance imaging (MRI) scan of the brain with and without contrast within 14 days prior to registration; the dose of steroids must be stable or decreasing for at least 5 days prior to the scan; patients with tumor progression who then undergo surgical resection prior to enrollment on study may be eligible as long as pathology confirms progressive or recurrent glioblastoma multiforme (GBM) (or variants); for patients who undergo surgical resection, registration on study may not occur any sooner than 28 days from surgery; an MRI scan of the brain with and without contrast is still required within 14 days prior to registration on study but is not required to demonstrate measurable disease or tumor progression after surgery
  • Patients unable to undergo MRI because of non-compatible devices can be enrolled, provided computed tomography (CT) scans are obtained and are of sufficient quality; patients without non-compatible devices may not have CT scans performed to meet this requirement
  • History/physical examination within 14 days prior to registration
  • Karnofsky performance scale >= 70
  • Patients who have received prior treatment with interstitial brachytherapy, stereotactic radiosurgery, or implanted chemotherapy sources, such as wafers of polifeprosan 20 with carmustine, must have confirmation of progressive disease within 14 days prior to registration based upon nuclear imaging, magnetic resonance (MR) spectroscopy, perfusion imaging, or histopathology
  • Leukocytes > 3,000/mm^3
  • Absolute neutrophil count (ANC) >= 1,500/mm^3
  • Hemoglobin >= 10.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dL is acceptable)
  • Platelets >= 100,000/mm^3
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal
  • Bilirubin =< 2.0 mg/dL
  • Creatinine within normal upper institutional limits or creatinine clearance > 60 mL/min/1.73 m^2 (per 24 hour urine collection or calculated according to the Cockcroft-Gault formula) for subjects with creatinine levels above the institutional normal

    • Patients with creatinine levels below normal institutional limits are eligible
  • Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
  • Urinary protein =< 30 mg/dL in urinalysis or =< 1+ on dipstick
  • Generally well-controlled blood pressure with systolic blood pressure =< 140 mm Hg AND diastolic blood pressure =< 90 mm Hg within 5 days prior to registration; the use of anti-hypertensive medications to control hypertension is permitted
  • Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test within 14 days prior to registration
  • Women of childbearing potential and male patients who are sexually active must practice adequate contraception during therapy and for 180 days (6 months) afterwards
  • Patient must provide study specific informed consent prior to study entry

Exclusion Criteria:

  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • Prior systemic cytotoxic chemotherapy within (ie, =<) 28 days (42 days for nitrosoureas or mitomycin C) prior to registration, or patients who have not returned to baseline or =< Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v. 4) grade 2 from adverse events (excluding alopecia) due to agents administered more than 28 days prior to registration
  • Patients who received non-cytotoxic drug therapy must be off treatment for at least 14 days prior to registration; prior treatment with anti-vascular endothelial growth factor (VEGF) targeted agents; AMG 386 therapy; or other molecules that inhibit angiopoietins or TEK tyrosine kinase, endothelial (Tie2) receptor including, but not limited to, XL-820, XL-184 (cabozantinib-s-malate), and CVX-060/PF-4856884 is not allowed regardless of time frame
  • Patients who have not yet completed at least 21 days (30 days for prior monoclonal antibody therapy) since ending other investigational device or drug trials, or who are currently receiving other investigational treatments
  • Treatment within 30 days prior to enrollment with strong immune modulators, including but not limited to systemic cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, lenalidomide, and targeted immune modulators such as abatacept (CTLA-4-Ig), adalimumab, alefacept, anakinra, belatacept (LEA29Y), efalizumab, etanercept, infliximab, or rituximab
  • Prior radiotherapy within 90 days (3 months) prior to registration unless there is either: a) histopathologic confirmation of recurrent tumor; or b) new enhancement on MRI outside of the radiation treatment field
  • Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 28 days prior to registration or those patients who receive an non-central nervous system (CNS) minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 3 days prior to registration; there is no waiting period for central line placement; there is a 7-day window for recovery prior to registration for patients who underwent stereotactic biopsy of the brain
  • Prior therapy with anti-VEGF targeted agents (e.g. bevacizumab, cediranib, vandetanib, aflibercept, sunitinib, sorafenib, etc.); prior therapy with thalidomide and lenalidomide is allowed as long as treatment has not occurred within 30 days prior to enrollment
  • More than 2 relapses
  • Therapeutic anticoagulation with warfarin < 7 days prior to registration; (therapeutic or prophylactic therapy with aspirin, a low-molecular weight heparin, or a Factor Xa inhibitor is acceptable)
  • Intratumoral hemorrhage or peritumoral hemorrhage, demonstrated by MRI or CT scan, CTCAE, v. 4 grade 2 or greater or evidence of significant hemorrhage (regardless of CTCAE, v. 4 grade) defined as > 1 cm diameter of blood (including postoperative hemorrhage)
  • Gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE, v. 4 grade 3 or greater within 30 days prior to study entry
  • Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization within 180 days (6 months) prior to registration
    • Transmural myocardial infarction within 180 days (6 months) prior to registration
    • History of stroke, cerebral vascular accident (CVA), or transient ischemic attack within 180 days (6 months) prior to registration
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
    • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
    • Known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past
    • History of non-healing wounds or ulcers, or bone fractures within 90 days (3 months) prior to registration
    • History of venous or arterial thromboembolism within 12 months prior to registration
  • Prior allergic reaction to the study drugs involved in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01609790

  Hide Study Locations
Locations
United States, Alaska
Alaska Breast Care and Surgery LLC Recruiting
Anchorage, Alaska, United States, 99508
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
Alaska Women's Cancer Care Recruiting
Anchorage, Alaska, United States, 99508
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
Anchorage Oncology Centre Recruiting
Anchorage, Alaska, United States, 99508
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
Katmai Oncology Group Recruiting
Anchorage, Alaska, United States, 99508
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
Providence Alaska Medical Center Recruiting
Anchorage, Alaska, United States, 99508
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
United States, Arizona
Arizona Oncology-Deer Valley Center Active, not recruiting
Phoenix, Arizona, United States, 85027
Arizona Oncology Services Foundation Recruiting
Scottsdale, Arizona, United States, 85260
Contact: David G. Brachman    800-360-6371      
Principal Investigator: David G. Brachman         
Arizona Oncology Associates-West Orange Grove Recruiting
Tucson, Arizona, United States, 85704
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
United States, California
Alta Bates Summit Medical Center-Herrick Campus Terminated
Berkeley, California, United States, 94704
Mills - Peninsula Hospitals Terminated
Burlingame, California, United States, 94010
Kaiser Permanente Los Angeles Medical Center Recruiting
Los Angeles, California, United States, 90027
Contact: Michael R. Girvigian    626-564-3455      
Principal Investigator: Michael R. Girvigian         
Los Angeles County-USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: Rose K. Lai    323-865-0451      
Principal Investigator: Rose K. Lai         
University of Southern California/Norris Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Rose K. Lai    323-865-0451      
Principal Investigator: Rose K. Lai         
Sutter Cancer Research Consortium Terminated
Novato, California, United States, 94945
Saint Joseph Hospital - Orange Recruiting
Orange, California, United States, 92868
Contact: Sam S. Huang    714-541-6622      
Principal Investigator: Sam S. Huang         
University of California Medical Center At Irvine-Orange Campus Recruiting
Orange, California, United States, 92868
Contact: Daniela A. Bota    877-827-8839    ucstudy@uci.edu   
Principal Investigator: Daniela A. Bota         
California Pacific Medical Center Terminated
San Francisco, California, United States, 94118
Sutter Solano Medical Center Terminated
Vallejo, California, United States, 94589
United States, Colorado
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Joshua H. Petit    970-482-3328      
Principal Investigator: Joshua H. Petit         
Poudre Valley Radiation Oncology Recruiting
Fort Collins, Colorado, United States, 80528
Contact: Joshua H. Petit    970-482-3328      
Principal Investigator: Joshua H. Petit         
United States, Connecticut
Saint Francis Hospital and Medical Center Recruiting
Hartford, Connecticut, United States, 06105
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
The Hospital of Central Connecticut Recruiting
New Britain, Connecticut, United States, 06050
Contact: Neal B. Goldberg    860-224-5660      
Principal Investigator: Neal B. Goldberg         
Eastern Connecticut Hematology and Oncology Associates Recruiting
Norwich, Connecticut, United States, 06360
Contact: Dennis E. Slater    860-886-8362      
Principal Investigator: Dennis E. Slater         
William Backus Hospital Recruiting
Norwich, Connecticut, United States, 06360
Contact: Dennis E. Slater    860-886-8362      
Principal Investigator: Dennis E. Slater         
United States, Florida
Broward Health Medical Center Recruiting
Fort Lauderdale, Florida, United States, 33316
Contact: Delia C. Guaqueta    954-355-5346      
Principal Investigator: Delia C. Guaqueta         
United States, Georgia
Piedmont Hospital Active, not recruiting
Atlanta, Georgia, United States, 30309
Piedmont Fayette Hospital Active, not recruiting
Fayetteville, Georgia, United States, 30214
Northeast Georgia Medical Center Recruiting
Gainesville, Georgia, United States, 30501
Contact: Frank G. Lake    770-219-8800    cancerpatient.navigator@nghs.com   
Principal Investigator: Frank G. Lake         
United States, Idaho
Saint Alphonsus Regional Medical Center Recruiting
Boise, Idaho, United States, 83706
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
United States, Illinois
Rush - Copley Medical Center Recruiting
Aurora, Illinois, United States, 60504
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Robert D. Aiken    312-942-5498    clinical_trials@rush.edu   
Principal Investigator: Robert D. Aiken         
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Jeffrey J. Raizer    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Jeffrey J. Raizer         
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Martin K. Nicholas    773-834-7424      
Principal Investigator: Martin K. Nicholas         
Carle on Vermilion Recruiting
Danville, Illinois, United States, 61832
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
Carle Physician Group-Effingham Recruiting
Effingham, Illinois, United States, 62401
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
NorthShore University HealthSystem-Evanston Hospital Active, not recruiting
Evanston, Illinois, United States, 60201
Illinois CancerCare-Galesburg Cottage Plaza Office Active, not recruiting
Galesburg, Illinois, United States, 61401
NorthShore University HealthSystem-Glenbrook Hospital Active, not recruiting
Glenview, Illinois, United States, 60026
Carle Physician Group-Mattoon/Charleston Recruiting
Mattoon, Illinois, United States, 61938
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
Community Cancer Center Foundation Recruiting
Normal, Illinois, United States, 61761
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Pekin Cancer Treatment Center Recruiting
Pekin, Illinois, United States, 61554
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
OSF Saint Francis Medical Center Recruiting
Peoria, Illinois, United States, 61637
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois Oncology Research Association CCOP Active, not recruiting
Peoria, Illinois, United States, 61615
OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC Recruiting
Peoria, Illinois, United States, 61615-7827
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
The Carle Foundation Hospital Recruiting
Urbana, Illinois, United States, 61801
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
Cadence Cancer Center in Warrenville Recruiting
Warrenville, Illinois, United States, 60555
Contact: Sean A. Grimm    630-352-5300    cancer@northwestern.edu   
Principal Investigator: Sean A. Grimm         
Rush-Copley Healthcare Center Recruiting
Yorkville, Illinois, United States, 60560
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
United States, Kansas
Saint Luke's South Hospital Recruiting
Overland Park, Kansas, United States, 66213
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Menorah Medical Center Recruiting
Overland Park, Kansas, United States, 66209
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Kansas City CCOP Recruiting
Prairie Village, Kansas, United States, 66208
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
United States, Kentucky
University of Kentucky Active, not recruiting
Lexington, Kentucky, United States, 40536
United States, Maine
Maine Medical Center- Scarborough Campus Recruiting
Scarborough, Maine, United States, 04074
Contact: Ian J. Bristol    207-396-8090    wrighd@mmc.org   
Principal Investigator: Ian J. Bristol         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106-0995
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Michigan Cancer Research Consortium Community Clinical Oncology Program Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Oakwood Hospital Recruiting
Dearborn, Michigan, United States, 48124
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Saint John Hospital and Medical Center Recruiting
Detroit, Michigan, United States, 48236
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Green Bay Oncology - Escanaba Recruiting
Escanaba, Michigan, United States, 49431
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Genesys Hurley Cancer Institute Recruiting
Flint, Michigan, United States, 48503
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Hurley Medical Center Recruiting
Flint, Michigan, United States, 48502
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Green Bay Oncology - Iron Mountain Recruiting
Iron Mountain, Michigan, United States, 49801
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Bronson Methodist Hospital Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
Borgess Medical Center Recruiting
Kalamazoo, Michigan, United States, 49001
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Saint Joseph Mercy Oakland Recruiting
Pontiac, Michigan, United States, 48341-2985
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Saint Joseph Mercy Port Huron Recruiting
Port Huron, Michigan, United States, 48060
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Saint Mary's of Michigan Recruiting
Saginaw, Michigan, United States, 48601
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
Saint John Macomb-Oakland Hospital Recruiting
Warren, Michigan, United States, 48093
Contact: Samir Narayan    734-712-3456      
Principal Investigator: Samir Narayan         
United States, Minnesota
Fairview Ridges Hospital Recruiting
Burnsville, Minnesota, United States, 55337
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Mercy Hospital Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Fairview-Southdale Hospital Recruiting
Edina, Minnesota, United States, 55435
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Unity Hospital Recruiting
Fridley, Minnesota, United States, 55432
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Hutchinson Area Health Care Active, not recruiting
Hutchinson, Minnesota, United States, 55350
Saint John's Hospital - Healtheast Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Minnesota Oncology Hematology PA-Maplewood Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Hennepin County Medical Center Recruiting
Minneapolis, Minnesota, United States, 55415
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Abbott-Northwestern Hospital Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
North Memorial Medical Health Center Recruiting
Robbinsdale, Minnesota, United States, 55422
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Metro-Minnesota CCOP Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Park Nicollet Clinic - Saint Louis Park Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
United Hospital Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Saint Francis Regional Medical Center Active, not recruiting
Shakopee, Minnesota, United States, 55379
Ridgeview Medical Center Recruiting
Waconia, Minnesota, United States, 55387
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Rice Memorial Hospital Recruiting
Willmar, Minnesota, United States, 56201
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Minnesota Oncology and Hematology PA-Woodbury Active, not recruiting
Woodbury, Minnesota, United States, 55125
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: Mark D. Anderson    601-815-6700      
Principal Investigator: Mark D. Anderson         
Singing River Hospital Recruiting
Pascagoula, Mississippi, United States, 39581
Contact: James E. Clarkson    228-809-5292      
Principal Investigator: James E. Clarkson         
United States, Missouri
Cape Radiation Oncology Terminated
Cape Girardeau, Missouri, United States, 63703
Centerpoint Medical Center LLC Recruiting
Independence, Missouri, United States, 64057
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Heartland Hematology and Oncology Associates Incorporated Recruiting
Kansas City, Missouri, United States, 64118
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
North Kansas City Hospital Terminated
Kansas City, Missouri, United States, 64116
Research Medical Center Recruiting
Kansas City, Missouri, United States, 64132
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Saint Luke's Hospital of Kansas City Recruiting
Kansas City, Missouri, United States, 64111
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Saint Luke's East - Lee's Summit Recruiting
Lee's Summit, Missouri, United States, 64086
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Liberty Hospital Recruiting
Liberty, Missouri, United States, 64068
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Saint John's Clinic-Rolla-Cancer and Hematology Active, not recruiting
Rolla, Missouri, United States, 65401
Heartland Regional Medical Center Recruiting
Saint Joseph, Missouri, United States, 64506
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Saint Joseph Oncology Inc Active, not recruiting
Saint Joseph, Missouri, United States, 64507
Saint John's Mercy Medical Center Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Jay W. Carlson    800-821-7532    sherrijr@iora.org   
Principal Investigator: Jay W. Carlson         
CoxHealth South Hospital Recruiting
Springfield, Missouri, United States, 65807
Contact: Jay W. Carlson    800-821-7532    sherrijr@iora.org   
Principal Investigator: Jay W. Carlson         
Mercy Hospital Springfield Recruiting
Springfield, Missouri, United States, 65804
Contact: Jay W. Carlson    800-821-7532    sherrijr@iora.org   
Principal Investigator: Jay W. Carlson         
Ozark Health Ventures LLC-Cancer Research for The Ozarks Springfield Active, not recruiting
Springfield, Missouri, United States, 65804
United States, Nebraska
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Tien-Shew W. Huang    402-354-5144      
Principal Investigator: Tien-Shew W. Huang         
United States, New York
New York Oncology Hematology PC - Albany Recruiting
Albany, New York, United States, 12206
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
New York Oncology Hematology PC -Albany Medical Center Recruiting
Albany, New York, United States, 12208
Contact: Susan A. Weaver    518-489-3612ext1342    sharon.krause@usoncology.com   
Principal Investigator: Susan A. Weaver         
Hematology Oncology Associates of Central New York-Auburn Recruiting
Auburn, New York, United States, 13021
Contact: Dennis J. Kotlove    315-472-7504      
Principal Investigator: Dennis J. Kotlove         
Montefiore Medical Center - Moses Campus Recruiting
Bronx, New York, United States, 10467-2490
Contact: Mary R. Welch    718-904-2730    aecc@aecom.yu.edu   
Principal Investigator: Mary R. Welch         
Hematology Oncology Associates of Central New York PC-East Syracuse Recruiting
East Syracuse, New York, United States, 13057
Contact: Dennis J. Kotlove    315-472-7504      
Principal Investigator: Dennis J. Kotlove         
Hematology Oncology Associates of Central New York-Liverpool Terminated
Liverpool, New York, United States, 13088
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Andrew B. Lassman    212-305-8615      
Principal Investigator: Andrew B. Lassman         
New York University Langone Medical Center Recruiting
New York, New York, United States, 10016
Contact: Joshua S. Silverman    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: Joshua S. Silverman         
Hematology Oncology Associates of Central New York-Rome Recruiting
Rome, New York, United States, 13440
Contact: Dennis J. Kotlove    315-472-7504      
Principal Investigator: Dennis J. Kotlove         
Hematology Oncology Associates of Central New York-Onondaga Hill Recruiting
Syracuse, New York, United States, 13215
Contact: Dennis J. Kotlove    315-472-7504      
Principal Investigator: Dennis J. Kotlove         
United States, North Carolina
Mission Hospital-Memorial Campus Recruiting
Asheville, North Carolina, United States, 28801
Contact: Christopher H. Chay    828-213-4150      
Principal Investigator: Christopher H. Chay         
Park Ridge Hospital Breast Health Center Recruiting
Hendersonville, North Carolina, United States, 28792
Contact: Patricia C. Griffin    800-486-5941      
Principal Investigator: Patricia C. Griffin         
Rutherford Hospital Terminated
Rutherfordton, North Carolina, United States, 28139
United States, Ohio
Summa Akron City Hospital/Cooper Cancer Center Recruiting
Akron, Ohio, United States, 44304
Contact: Charles A. Kunos    330-375-6101      
Principal Investigator: Charles A. Kunos         
Akron General Medical Center Active, not recruiting
Akron, Ohio, United States, 44307
Summa Barberton Hospital Recruiting
Barberton, Ohio, United States, 44203
Contact: Charles A. Kunos    330-375-6101      
Principal Investigator: Charles A. Kunos         
Strecker Cancer Center-Belpre Recruiting
Belpre, Ohio, United States, 45714
Contact: Mark J. Becker    614-566-4475      
Principal Investigator: Mark J. Becker         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45267
Contact: Kevin P. Redmond    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Kevin P. Redmond         
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Mount Carmel Health Center West Recruiting
Columbus, Ohio, United States, 43222
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Columbus Oncology and Hematology Associates Inc Recruiting
Columbus, Ohio, United States, 43214
Contact: Mark J. Becker    614-566-4475      
Principal Investigator: Mark J. Becker         
Columbus CCOP Recruiting
Columbus, Ohio, United States, 43215
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Doctors Hospital Recruiting
Columbus, Ohio, United States, 43228
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Delaware Health Center-Grady Cancer Center Recruiting
Delaware, Ohio, United States, 43015
Contact: Mark J. Becker    614-566-4475      
Principal Investigator: Mark J. Becker         
Delaware Radiation Oncology Recruiting
Delaware, Ohio, United States, 43015
Contact: Mark J. Becker    614-566-4475      
Principal Investigator: Mark J. Becker         
Grady Memorial Hospital Recruiting
Delaware, Ohio, United States, 43015
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Lancaster Radiation Oncology Recruiting
Lancaster, Ohio, United States, 43130
Contact: Mark J. Becker    614-566-4475      
Principal Investigator: Mark J. Becker         
Fairfield Medical Center Recruiting
Lancaster, Ohio, United States, 43130
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Marietta Memorial Hospital Recruiting
Marietta, Ohio, United States, 45750
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Summa Health Center at Lake Medina Recruiting
Medina, Ohio, United States, 44256
Contact: Charles A. Kunos    330-375-6101      
Principal Investigator: Charles A. Kunos         
Knox Community Hospital Recruiting
Mount Vernon, Ohio, United States, 43050
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Licking Memorial Hospital Recruiting
Newark, Ohio, United States, 43055
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Newark Radiation Oncology Recruiting
Newark, Ohio, United States, 43055
Contact: Mark J. Becker    614-566-4475      
Principal Investigator: Mark J. Becker         
Southern Ohio Medical Center Recruiting
Portsmouth, Ohio, United States, 45662
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Robinson Radiation Oncology Active, not recruiting
Ravenna, Ohio, United States, 44266
Springfield Regional Medical Center Recruiting
Springfield, Ohio, United States, 45505
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
University Pointe Recruiting
West Chester, Ohio, United States, 45069
Contact: Kevin P. Redmond    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Kevin P. Redmond         
Saint Ann's Hospital Recruiting
Westerville, Ohio, United States, 43081
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Genesis HealthCare System Recruiting
Zanesville, Ohio, United States, 43701
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Terence S. Herman    405-271-4272    julie-traylor@ouhsc.edu   
Principal Investigator: Terence S. Herman         
Oklahoma Oncology Inc Active, not recruiting
Tulsa, Oklahoma, United States, 74104
Tulsa Cancer Institute Recruiting
Tulsa, Oklahoma, United States, 74146
Contact: Terence S. Herman    405-271-4272    julie-traylor@ouhsc.edu   
Principal Investigator: Terence S. Herman         
Natalie Warren Bryant Cancer Center at Saint Francis Active, not recruiting
Tulsa, Oklahoma, United States, 74136
Warren Cancer Research Foundation Active, not recruiting
Tulsa, Oklahoma, United States, 74136
United States, Oregon
Clackamas Radiation Oncology Center Recruiting
Clackamas, Oregon, United States, 97015
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
Willamette Valley Cancer Center Recruiting
Eugene, Oregon, United States, 97401
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
Providence Saint Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
Western Oncology Research Consortium Recruiting
Portland, Oregon, United States, 97213
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
United States, Pennsylvania
UPMC - HVHS Cancer Center at Heritage Valley Beaver Recruiting
Beaver, Pennsylvania, United States, 15009
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
Saint Luke's University Hospital-Bethlehem Campus Recruiting
Bethlehem, Pennsylvania, United States, 18015
Contact: Neil D. Belman    610-954-3582    infolink@slhn.org   
Principal Investigator: Neil D. Belman         
Bryn Mawr Hospital Recruiting
Bryn Mawr, Pennsylvania, United States, 19010
Contact: Albert S. DeNittis    866-225-5654      
Principal Investigator: Albert S. DeNittis         
UPMC Cancer Center at Jefferson Regional Medical Center Recruiting
Clairton, Pennsylvania, United States, 15025
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
UPMC Cancer Center at UPMC Horizon Recruiting
Farrell, Pennsylvania, United States, 16121
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
Adams Cancer Center Recruiting
Gettysburg, Pennsylvania, United States, 17325
Contact: Amit B. Shah    877-441-7957      
Principal Investigator: Amit B. Shah         
UPMC Cancer Centers - Arnold Palmer Pavilion Recruiting
Greensburg, Pennsylvania, United States, 15601
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
Cherry Tree Cancer Center Recruiting
Hanover, Pennsylvania, United States, 17331
Contact: Amit B. Shah    877-441-7957      
Principal Investigator: Amit B. Shah         
UPMC-Johnstown/John P. Murtha Regional Cancer Center Recruiting
Johnstown, Pennsylvania, United States, 15901
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
Lancaster General Hospital Recruiting
Lancaster, Pennsylvania, United States, 17604
Contact: Jeffery S. Eshleman    717-544-5511      
Principal Investigator: Jeffery S. Eshleman         
UPMC Cancer Center at UPMC McKeesport Recruiting
McKeesport, Pennsylvania, United States, 15132
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
UPMC Cancer Center-Natrona Heights Recruiting
Natrona Heights, Pennsylvania, United States, 15065
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
Jameson Health System North Campus Recruiting
New Castle, Pennsylvania, United States, 16105
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
Paoli Memorial Hospital Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Albert S. DeNittis    866-225-5654      
Principal Investigator: Albert S. DeNittis         
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Lyndon J. Kim    215-955-6084    laura.lefko@umassmed.edu   
Principal Investigator: Lyndon J. Kim         
UPMC-Shadyside Hospital Active, not recruiting
Pittsburgh, Pennsylvania, United States, 15232
UPMC-Saint Clair Hospital Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15243
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
UPMC-Passavant Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15237
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
University of Pittsburgh Medical Center-Presbyterian Hospital Active, not recruiting
Pittsburgh, Pennsylvania, United States, 15213
UPMC-Saint Margaret Recruiting
Pittsburgh, Pennsylvania, United States, 15215
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
UPMC Cancer Center at UPMC Northwest Recruiting
Seneca, Pennsylvania, United States, 16346
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
UPMC-Uniontown/Robert E. Eberly Pavilion Recruiting
Uniontown, Pennsylvania, United States, 15401
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
Washington Hospital Recruiting
Washington, Pennsylvania, United States, 15301
Contact: Frank S. Lieberman    412-647-8073      
Principal Investigator: Frank S. Lieberman         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Albert Yuen    610-988-9323      
Principal Investigator: Albert Yuen         
Lankenau Hospital Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Albert S. DeNittis    866-225-5654      
Principal Investigator: Albert S. DeNittis         
Mainline Health CCOP Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Albert S. DeNittis    866-225-5654      
Principal Investigator: Albert S. DeNittis         
WellSpan Health-York Hospital Recruiting
York, Pennsylvania, United States, 17405
Contact: Amit B. Shah    877-441-7957      
Principal Investigator: Amit B. Shah         
United States, South Carolina
AnMed Health Cancer Center Recruiting
Anderson, South Carolina, United States, 29621
Contact: David S. Martoccia    864-512-1000    rballew@anmedhealth.org   
Principal Investigator: David S. Martoccia         
Gibbs Cancer Center-Pelham Recruiting
Greer, South Carolina, United States, 29651
Contact: Patricia C. Griffin    800-486-5941      
Principal Investigator: Patricia C. Griffin         
Spartanburg Regional Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Patricia C. Griffin    800-486-5941      
Principal Investigator: Patricia C. Griffin         
Upstate Carolina CCOP Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Patricia C. Griffin    800-486-5941      
Principal Investigator: Patricia C. Griffin         
United States, South Dakota
Rapid City Regional Hospital Recruiting
Rapid City, South Dakota, United States, 57701
Contact: Michael J. Swartz    605-716-3982    research@rcrh.org   
Principal Investigator: Michael J. Swartz         
United States, Texas
Texas Oncology - Central Austin Cancer Center Recruiting
Austin, Texas, United States, 78731
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Texas Oncology-Austin Midtown Recruiting
Austin, Texas, United States, 78705
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Texas Oncology - South Austin Cancer Center Recruiting
Austin, Texas, United States, 78745
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Texas Oncology PA - Bedford Active, not recruiting
Bedford, Texas, United States, 76022
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Edward Pan    214-648-7097    canceranswers@moffitt.org   
Principal Investigator: Edward Pan         
Texas Oncology at Baylor Charles A Sammons Cancer Center Recruiting
Dallas, Texas, United States, 75246
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
The Klabzuba Cancer Center Recruiting
Fort Worth, Texas, United States, 76104
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Texas Oncology-Grapevine Recruiting
Grapevine, Texas, United States, 76053
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Texas Oncology-Longview Cancer Center Recruiting
Longview, Texas, United States, 75601
Contact: Bernard W. Taylor    903-757-2122      
Principal Investigator: Bernard W. Taylor         
Texas Oncology - Round Rock Cancer Center Recruiting
Round Rock, Texas, United States, 78681
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Texas Oncology-Seton Williamson Recruiting
Round Rock, Texas, United States, 78665
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Texas Oncology Cancer Center Sugar Land Recruiting
Sugar Land, Texas, United States, 77479
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
Tyler Cancer Center Recruiting
Tyler, Texas, United States, 75702
Contact: Vivek S. Kavadi    281-277-5200      
Principal Investigator: Vivek S. Kavadi         
United States, Utah
Huntsman Intermountain Cancer Center-American Fork Hospital Recruiting
American Fork, Utah, United States, 84003
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
Sandra L Maxwell Cancer Center Recruiting
Cedar City, Utah, United States, 84720
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
Logan Regional Hospital Recruiting
Logan, Utah, United States, 84321
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
Intermountain Medical Center Recruiting
Murray, Utah, United States, 84157
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
McKay-Dee Hospital Center Recruiting
Ogden, Utah, United States, 84403
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
Utah Valley Regional Medical Center Recruiting
Provo, Utah, United States, 84604-3337
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
Dixie Medical Center Regional Cancer Center Recruiting
Saint George, Utah, United States, 84770
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
Utah Cancer Specialists-Salt Lake City Recruiting
Salt Lake City, Utah, United States, 84106
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
LDS Hospital Recruiting
Salt Lake City, Utah, United States, 84143
Contact: Paula K. Rauschkolb    801-507-3950      
Principal Investigator: Paula K. Rauschkolb         
United States, Washington
Cancer Care Northwest - Spokane South Active, not recruiting
Spokane, Washington, United States, 99202
Cancer Care Northwest-North Spokane Active, not recruiting
Spokane, Washington, United States, 99218
Compass Oncology Vancouver Recruiting
Vancouver, Washington, United States, 98684
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
PeaceHealth Southwest Medical Center Recruiting
Vancouver, Washington, United States, 98664
Contact: Matthew C. Solhjem    503-215-6412      
Principal Investigator: Matthew C. Solhjem         
United States, Wisconsin
Langlade Hospital and Cancer Center Recruiting
Antigo, Wisconsin, United States, 54409
Contact: Darryl R. Barton    877-405-6866      
Principal Investigator: Darryl R. Barton         
Saint Mary's Hospital Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Saint Vincent Hospital Recruiting
Green Bay, Wisconsin, United States, 54301
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Green Bay Oncology Limited at Saint Mary's Hospital Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Green Bay Oncology at Saint Vincent Hospital Recruiting
Green Bay, Wisconsin, United States, 54301-3526
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: H. I. Robins    877-405-6866      
Principal Investigator: H. I. Robins         
Holy Family Memorial Hospital Recruiting
Manitowoc, Wisconsin, United States, 54221
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Bay Area Medical Center Recruiting
Marinette, Wisconsin, United States, 54143
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Community Memorial Hospital Recruiting
Menomonee Falls, Wisconsin, United States, 53051
Contact: Jennifer M. Connelly    414-805-4380      
Principal Investigator: Jennifer M. Connelly         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Jennifer M. Connelly    414-805-4380      
Principal Investigator: Jennifer M. Connelly         
D N Greenwald Center Recruiting
Mukwonago, Wisconsin, United States, 53149
Contact: Wingate F. Clapper    262-928-7632      
Principal Investigator: Wingate F. Clapper         
Cancer Center of Western Wisconsin Recruiting
New Richmond, Wisconsin, United States, 54017
Contact: Paul W. Sperduto    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Paul W. Sperduto         
Oconomowoc Memorial Hospital-ProHealth Care Inc Recruiting
Oconomowoc, Wisconsin, United States, 53066-3896
Contact: Wingate F. Clapper    262-928-7632      
Principal Investigator: Wingate F. Clapper         
Green Bay Oncology - Oconto Falls Recruiting
Oconto Falls, Wisconsin, United States, 54154
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Green Bay Oncology - Sturgeon Bay Recruiting
Sturgeon Bay, Wisconsin, United States, 54235
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Door County Cancer Center Recruiting
Sturgeon Bay, Wisconsin, United States, 54235-1495
Contact: James L. Leenstra    920-433-8889      
Principal Investigator: James L. Leenstra         
Waukesha Memorial Hospital - ProHealth Care Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Wingate F. Clapper    262-928-7632      
Principal Investigator: Wingate F. Clapper         
Aspirus Regional Cancer Center Recruiting
Wausau, Wisconsin, United States, 54401
Contact: Darryl R. Barton    877-405-6866      
Principal Investigator: Darryl R. Barton         
Canada, Saskatchewan
Allan Blair Cancer Centre Recruiting
Regina, Saskatchewan, Canada, S4T 7T1
Contact: Rashmi Koul    866-561-1026    CIO_Web@cancercare.mb.ca   
Principal Investigator: Rashmi Koul         
Sponsors and Collaborators
Investigators
Principal Investigator: Eudocia Lee NRG Oncology
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01609790     History of Changes
Other Study ID Numbers: NCI-2012-01969, NCI-2012-01969, CDR0000734205, RTOG 1122, RTOG-1122, U10CA180868, U10CA021661
Study First Received: May 30, 2012
Last Updated: July 15, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Brain Neoplasms
Glioblastoma
Oligodendroglioma
Gliosarcoma
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antibodies
Antibodies, Monoclonal
Bevacizumab
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on July 20, 2014